28 papers in the library · 1 citation · publishing 2019-2026
Mental Health Weekly February 15, 2021 Valerie A. Canady
Prior use of selective serotonin reuptake inhibitors (SSRIs) may reduce the effectiveness of 3,4‐methylenedioxymethamphetamine (MDMA)‐assisted therapy for post‐traumatic stress disorder (PTSD), say researchers of a recent study who noted that MDMA is close to being considered the first psychedelic drug approved to treat PTSD.
Mental Health Weekly August 10, 2020 Valerie A. Canady
The Food and Drug Administration (FDA) announced Aug. 3 approval of Janssen Pharmaceutical's supplemental new drug application (sNDA) for the expanded use of SPRAVATO esketamine Clll nasal spray for the treatment of major depressive disorder (MDD) with acute suicidal ideation or behavior. SPRAVATO was initially approved by the FDA March 5, 2019, for the treatment of treatment‐resistant depression.
Mental Health Weekly February 25, 2019 Valerie A. Canady
A Food and Drug Administration (FDA) advisory committee earlier this month recommended the approval of a ketamine nasal spray treatment for adults with treatment‐resistant depression. Recent research has shown that ketamine treatment is gaining traction as an effective treatment for people struggling with depression.